Outbound Relationships |
Type |
Target |
Active |
Characteristic |
Refinability |
Group |
Values |
tositumomab 14 mg/ml/jod-131 5,6 mCi/ml/tositumomab 1,1 mg/ml injektionsvæske, hætteglas |
Is a |
Product containing tositumomab (medicinal product) |
false |
Inferred relationship |
Some |
|
|
tositumomab 14 mg/ml/jod-131 5,6 mCi/ml/tositumomab 1,1 mg/ml injektionsvæske, hætteglas |
Is a |
Product containing iodine-131 (medicinal product) |
false |
Inferred relationship |
Some |
|
|
tositumomab 14 mg/ml/jod-131 5,6 mCi/ml/tositumomab 1,1 mg/ml injektionsvæske, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Iodine radioisotope |
false |
Inferred relationship |
Some |
|
|
tositumomab 14 mg/ml/jod-131 5,6 mCi/ml/tositumomab 1,1 mg/ml injektionsvæske, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Immunosuppressant (substance) |
false |
Inferred relationship |
Some |
|
|
tositumomab 14 mg/ml/jod-131 5,6 mCi/ml/tositumomab 1,1 mg/ml injektionsvæske, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Tositumomab (substance) |
false |
Inferred relationship |
Some |
|
|
tositumomab 14 mg/ml/jod-131 5,6 mCi/ml/tositumomab 1,1 mg/ml injektionsvæske, hætteglas |
Has manufactured dose form |
injektionsvæske |
false |
Inferred relationship |
Some |
|
|
tositumomab 14 mg/ml/jod-131 5,6 mCi/ml/tositumomab 1,1 mg/ml injektionsvæske, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
radiofarmaceutisk middel |
false |
Inferred relationship |
Some |
|
|
tositumomab 14 mg/ml/jod-131 5,6 mCi/ml/tositumomab 1,1 mg/ml injektionsvæske, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Iodine-131 (substance) |
false |
Inferred relationship |
Some |
|
|
tositumomab 14 mg/ml/jod-131 5,6 mCi/ml/tositumomab 1,1 mg/ml injektionsvæske, hætteglas |
Is a |
Product manufactured as parenteral dose form (product) |
false |
Inferred relationship |
Some |
|
|